Patients with advanced metastatic melanoma are often confronted with little prospect of medium-to longer-term survival by any currently available therapeutic means. However, most clinicians are aware of exceptional cases where survival defies the notion of futility. Prolonged survival from immunotherapies, including interleukin-2, vaccines and antibodies to cytotoxic lymphocyte antigen-4, and programmed death-1 receptor inhibitory monoclonal antibody, implies a role for immune system modulation. We aimed to identify cases where exceptional survival from advanced melanoma occurred prior to recent novel therapies to facilitate better understanding of this phenomenon. Methods: Cases of long-term survival of $3 years' duration (from diagnosis of metastatic disease) were identified from the database of one clinician; these cases were treated before the availability of newer immunotherapies, and they were documented and examined. A literature search for reported outcome measures from published studies using older and recent therapies for advanced melanoma was conducted to enable the comparison of data. Results: Eighteen cases were identified that identified survival of $3 years' duration from metastatic disease (12 American Joint Committee on Cancer [AJCC] Stage IV cases; six AJCC III cases) diagnosis. These were assessed and reported to detail the clinical course. Standard clinical prognostication methods predicted high risk of early mortality in those patients. No identifiable differences could be detected between these and other patients with similar patterns of disease. At evaluation, 17 patients (94%) had survived $5 years, and eleven patients (61%) had survived $10 years (range: 3-15 years). The median survival duration with metastatic disease was 11 years; 15 remained alive and three had died. Published studies of melanoma therapies were tabled for comparison.
Current standard therapy for primary melanoma is wide local excision (WLE) of the skin and subcutaneous tissues around the primary lesion with surgical margins determined by Breslow thickness. 6, 7 Lymphatic tracing and sentinel node biopsy is recommended for melanomas .1 mm in thickness for staging and therapy because regional draining lymph nodes are typically the first site of metastases. 8 The status of the sentinel nodes is the most important prognostic factor in patients with primary melanoma. Patients with regional or local lymphatic spread have a high risk of widespread disseminated disease and poorer survival rates. 7 Observed patterns of metastases are, however, highly variable.
While localized disease can be effectively managed with surgery, there is currently no effective treatment for disseminated disease. Management options differ depending on the sites and rate of progression of the disease and usually involve a multidisciplinary approach. Surgical resection of operable metastases has been shown to significantly improve the patient's survival rate, but is predominantly employed only if one or few metastases are present and resectable. 3, [9] [10] [11] Adjuvant radiotherapy may be employed postoperatively; however, several studies have demonstrated no improvement in survival when used after nodal dissection in stage III patients, [12] [13] [14] while one showed improved local disease control. 15 In advanced disease, radiotherapy plays a larger role in effective symptom palliation, especially for bone metastases.
Standard approved chemotherapy with single-agent dacarbazine, fotemustine, or temozolomide has been used for the treatment of late-stage melanoma; however, overall response rates (ORR) remain uniformly low (5%-20%) and are often short lived. 2, 3 Complete responses (CRs) from chemotherapy are rare. Isolated limb perfusion or infusion chemotherapy techniques are effective for recurrent disease localized to the arm or the leg and have reported regional CR rates of between 40% and 60%. 12, 16, 17 Recent advances in the development of inhibitory agents, which target key checkpoint molecules within metabolic pathways of melanoma cells, have led to a range of new experimental therapies. These include B-raf and mitogenactivated protein kinase inhibitors, which offer much promise for the more effective treatment of selected B-raf mutationpositive advanced melanoma. 17, 18 However, despite some impressive initial clinical responses, these seldom translate into CRs or durable long-term survival.
Immunotherapy has also emerged over the last three decades as a potentially viable field of therapy. In particular, interleukin-2 (IL-2), cytotoxic lymphocyte antigen-4 (CTLA-4), and programmed death receptor-1 (PD-1), and programmed death-1 receptor ligand inhibitory monoclonal antibody (PDL-1) therapies, vaccines, and other cytokinebased therapies have been a major area of research. [18] [19] [20] Notably, IL-2 therapy has stood the test of time, with some 5%-10% of patients achieving CRs and long-term survival. 21, 22 More recently, studies have demonstrated a 17% CR rate from combined CTLA-4 inhibitor and IL-2 therapy and similar CR rates using a melanoma lysate vaccine therapy. 17, 20, 23 In contrast to the pathway inhibitors, immunotherapeutic strategies produce higher reported rates of CRs and are associated with a higher proportion of long-term survivors. 20, 23 Importantly, almost irrespective of the therapy type considered, when CRs occur, these often translate into long-term survival beyond 5 years, especially for immunotherapies.
Objectives
The primary objective of this study was to identify and document advanced melanoma cases where longer-term survival of at least 3 years was observed, in one clinician's experience. A second objective was to evaluate the published literature to date for reported clinical outcomes from advanced melanoma therapies.
Methods
The case records of patients under the care of one clinician (BJC) were carefully reviewed and those with a survival 
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long-term survival in advanced melanoma of $3 years from the date of diagnosis of metastatic disease were identified. Treatment modalities and event timelines were recorded and investigated for each patient. For the purposes of the study, data collection was ceased in April 2013. The literature was surveyed using PubMed and other databases for published clinical trials of agents that have been successfully used for the systemic treatment of metastatic melanoma from 1984. Search terms included: "metastatic melanoma"; "advanced melanoma"; "systemic therapy"; "complete response"; "CR"; "chemotherapy"; "DTIC"; "dacarbazine"; "temozolomide"; "fotemustine"; "IL-2"; "interleukin-2"; "pathway inhibitors"; "immunotherapy"; "vaccine"; "B-raf "; "Braf "; "CTLA-4"; and "PD-1". Reported studies that utilized chemotherapy and other therapies for the treatment of advanced or metastatic melanoma were identified and included.
Results
The median age was 55 years at melanoma presentation, with ages ranging from 33 to 83 years. The median duration of survival from the initial diagnosis of primary melanoma was 13.5 years. All individuals were Caucasian. Fourteen were male and three were female. American Joint Committee on cancer (AJCC) staging determined that there were 12 cases with stage IV and six with advanced stage III disease present at the time of initial therapy or observation. At the time of data collection closure, 18 patients were identified who had survived for $3 years after the diagnosis of advanced melanoma, ranging from 3 to 15 years in duration. Seventeen patients (94%) had survived 5 years or more and eleven patients (61%) had survived 10 years or more.
The median survival duration with metastatic disease was 11 years. At evaluation, 15 remained alive and three were dead (Table 1) .
Detailed case series
Case a (status: alive and disease-free; survival: 11 years) May 2010, "palliative" left radical high pelvic retroperitoneal lymph node dissection was performed. The combined timed vaccine and chemotherapy regimen was recommenced, until DTIC was ceased in December 2010 due to bone marrow suppression and low blood counts. All metastases regressed completely and repeated regular computed tomography (CT) scans have revealed no evidence of metastatic disease since.
Case C (status: died in april 2011; survival: 3 years)
A 57-year-old male presented in May 2005 for amputation of his right middle finger for advanced subungual acral lentiginous melanoma, Clark level IV, Breslow depth 2.5 mm. In January 2008, he was found to have bilateral pulmonary metastases and he was commenced on six cycles of DTIC, which successfully reduced the size of these tumors by November 2008. In June 2009, CT scans showed progression of a right hilar mass and the patient was commenced on fotemustine, which was not effective. In February 2010, he began a trial of timed administration of the VMCL vaccine with oral cyclophosphamide (2×50 mg doses per day intermittently) with immune monitoring based on high-sensitivity C-reactive protein levels. Stability of disease was observed for 2 months. In April 2010, a left ischiorectal fossa melanoma metastasis was surgically resected. In August 2010, a CT scan revealed further pulmonary, hepatic, and bony metastases. Radiotherapy was given to the right hilar metastatic deposit and mediastinum, with some success. In September 2010, he developed a metastasis to his left buttock, which was completely excised, and in October he went on to develop multiple subcutaneous metastases to his scalp, neck, and jaw. He recommenced palliative treatment with DTIC chemotherapy in November, but failed to respond. In January 2011, he was noted to have an increasingly severe cough and had developed subsequent pneumonia with pleural effusions. The pleural effusions were drained but he recovered incompletely and died.
Case D (status: alive and disease-free; survival: 13 years)
A 58-year-old male presented in 2000 with malignant melanoma in the liver, with no identified primary tumor. This was completely resected, and he went on to develop metastases to his scalp in 2001, which were also completely excised. Chemotherapy was declined. He has remained well since. No other treatment apart from self-termed "positive thinking" was instituted.
Case e (status: died in March 2010; survival: 8 years)
A Case M (status: alive and disease-free; survival: 13 years)
A 48-year-old Caucasian male presented in 2000 with a 4 cm diameter right axillary lump present for 7 months with no primary melanoma site identified. A fine-needle biopsy confirmed metastatic melanoma and he was booked for a right radical axillary lymph node dissection, but this was deferred so the patient could attend the Sydney Olympic Games. On review 6 weeks later, the mass had markedly reduced in size.
The mass continued to decrease in size without treatment, and a CT scan at that time showed no evidence of disease. On recent repeat CT scanning in 2010, no metastatic disease was evident, and clinically he continues to be disease-free.
Case n (status: alive and disease-free; survival: 10 years) 
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Coventry et al 2009, the patient re-presented with a second primary Clark level IV, Breslow 0.85 mm thick metastasis to his right thigh, which was surgically excised. For the purposes of comparison, the reported relevant clinical outcome measures for a range of different published treatment modalities for metastatic melanoma are shown in Table 2 .
Discussion
The finding that 18 patients with metastatic melanoma had remained alive for $3 years' duration, and that 17 had survived $5 years, was both unusual and notable. Despite considerable research into multiple areas of treatment, the overall usual prognosis of stage IV melanoma still remains poor. Median survival time ranges from 6 to 9 months, with a 5-year survival rate of ,2%.
1-3 Although there have been recent encouraging therapeutic approaches using pathway and checkpoint blockade approaches and some indication of prolongation of survival, in many centers, the typical treatment options for disseminated disease still remain seriously limited in their ability to induce long-term survival. [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] Surgical resection can be very effective in selected cases if the metastases are solitary or few in number, or if they are sequential in their clinical appearance, 9-11 but this is unpredictable with recurrence being commonplace.
Until recently, DTIC has often been considered the first-line treatment for patients with disseminated disease, conferring response rates of 10%-20% and producing initial complete remission in 0%-5% of patients. 14, 24 Despite this, the 5-year survival rate for patients using this therapy remains under 2%, and three separate randomized controlled trials conducted by the European Organization for Research and Treatment of Cancer, the World Health Organization, and the Central Oncology Group demonstrated no significant difference in survival after treatment with DTIC compared with placebo. 6 Combination chemotherapy has offered little over singleagent chemotherapy for metastatic melanoma. Studies of nitrosourea-and DTIC-based chemotherapy, taxane-based chemotherapy, and cisplatin-based chemotherapy have found no convincing evidence to support improved efficacy. 6 Immunotherapy has been an emerging area of research over the past two decades with mixed results. 40 Several studies have examined the value of combined chemotherapy and immunotherapy, again with mixed results. Studies have looked at the role of interferon-α in combination with DTIC, cisplatin, vinca alkaloids, and nitrosoureas and found that the results were comparable to single-agent chemotherapy. 6 Similarly, treatment with IL-2 and DTIC has not been shown to be superior to single-agent therapy. In contrast, Phase II trials directed toward the combination of cisplatin and high-dose IL-2 or low-dose IL-2 with the addition of interferon-α showed initial promising results with response rates of 10%-20% and an overall 2-year survival rate of 10% in selected patients. 6 Unfortunately, due to the long inpatient hospital stays, high expense, and substantial toxicity, further Phase III investigations were considered not feasible.
Historically, meta-analyses focusing on the use of chemotherapy and immunotherapy in stage IV melanoma have shown their role to be largely palliative rather than curative. However, the concept of vaccines to directly target melanoma cells is particularly attractive. Several vaccine therapies have been investigated, with mixed results. One such example is the polyvalent allogenic whole-cell vaccine, CancerVax. Though early Phase I and II trials were encouraging, Phase III trials of the vaccine in both stage III and IV melanoma patients were discontinued due to negative findings. 40 Similarly, neither of the two lysate vaccines that entered Phase III clinical trials -the viral melanoma oncolysate vaccine and the aforementioned VMCL vaccine -have shown statistically significant survival benefit in surgically resected high-risk stage II/III melanoma patients 19 although, remarkably, VMCL has shown CR rates of 17% with a 15% 5-year survival rate for advanced stage III/IV metastatic melanoma. 23, 42 Recent reports using B-raf inhibitors (vemurafenib, dabrafenib) and CTLA-4 blocking antibody therapies (ipilimumab) had promised new hope for improving survival with stage IV melanoma. However, although overall response rates were 69% and 7%, the CR rates have remained very low at 0.9% and 0.5%, respectively. 26, 27, 41 It should be noted that, B-raf V600E expression has been found in 30%-60% of melanomas and that some 69% of these showed a response to B-raf inhibitory antibody therapy, then the true response rate for statistically valid comparison with the unselected melanoma patient population was about 31% (ie, 69% of 45%) overall. 26, 27 Despite the numerous discouraging results from studies of many therapies for advanced melanoma, some patients defy the usual predicted course of the disease. Those cases cited and detailed in this study represent extraordinary and informative cases. Close evaluation of these patients indicated that their pattern of disease was not uniform. Many of the patients had disease that was indistinguishable from other patients who subsequently encountered progressive disease and died. The main distinguishing feature for many of the patients cited here seemed to be the utilization of a range of 
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long-term survival in advanced melanoma therapies, often in sequence. This persistence and repetition in the clinical application of therapies appears to be a vitally important factor for determining patient survival. [42] [43] [44] The wide disparity between the multitude of variables in those cases reported here was far too divergent to permit useful correlative analysis. That wide divergence further adds to our contention that these cases most likely represent in vivo immunomanipulation of a pre-existing endogenous immune response against the cancer in the patient, often by multiple means, to create successful outcomes. 44 The investigation of multiple other pathways, such as neuroendocrine, glucocorticoid, melanogenic, and immunomodulatory influences, may offer associated approaches for overcoming the "resistance" mechanisms that appear to be evident with current therapies. 45 The interesting findings emerging from recent immunotherapeutic agents and strategies appear to be strongly indicative that modulation of a pre-existing, underlying, endogenous immune response is naturally occurring within the patient against their cancer. It is therefore highly likely that both the findings arising from the repeated therapies reported in our present series, and those being reported using current repetitious immunotherapeutic and pathway blockade therapy approaches, appear to cause progressive immunomodulation, perhaps by effectively "synchronising", "directing", or "re-focussing" the patient's in vivo immune response against their cancer. 42, 43 Better serial blood biomarker analysis and improvement of the accuracy of the timing of therapeutic intervention(s) both appear to be very promising approaches toward obtaining better "synchronization" of therapies with pre-existing in vivo immune responses to thereby improve clinical efficacy.
21,22,42-44

Conclusion
Some patients show long-term survival despite advanced melanoma having the reputation of being associated with a particularly dismal prognosis. Clinical course data for 18 cases demonstrates that some patients do defy the odds, in some cases even without therapy, to mount an effective response against their cancer. A combination of selective and combined therapies tailored to the individual patient appears to be capable of modulating the immune response and disease level in a favorable direction for a better outcome. These remarkable cases provide clinical insight into the mechanisms that underpin the better clinical control of metastatic melanoma, and perhaps cancer more generally. Even after failed treatment attempts, long-term patient survival may still be evidenced in a remarkable number of cases in clinical practice. Recent data from the treatment of patients using "pure" immunotherapeutic approaches, such as IL-2, CTLA-4/PD-1 antibody therapies, and repetitive vaccination, would reinforce the notion that restimulation of the immune response in the patient can be remarkably effective in inducing long-term survival.
Although the outlook on metastatic melanoma may seem dismal, cases such as those reported should provide patients with tangible evidence and some hope that their fight against advanced melanoma is not uniformly, nor irrevocably, futile. Physicians, while being realistic, should encourage patients not to become disheartened by failed treatment attempts. Some individuals, even after multiple failed treatment attempts, do ultimately defy their metastatic disease to outlive their initial predicted prognosis, as our findings demonstrate. Continued persistent therapies appear remarkably pivotal. Moreover, newer immunotherapies and new approaches for applying these clinically offer the very tangible prospects of improving the manipulation of endogenous immune responses in patients with advanced cancer.
